Menu Search
Equities

FSD Pharma Inc

0K9:FRA

FSD Pharma Inc

Actions
  • Price (EUR)0.29
  • Today's Change0.017 / 6.03%
  • Shares traded-1.00
  • 1 Year change-70.04%
  • Beta--
Data delayed at least 15 minutes, as of May 21 2024 07:16 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

FSD Pharma Inc. is a Canada-based biotechnology company. The Company operates through two segments: Biotechnology and Strategic Investments. Its Biotechnology segment is focused on furthering the research and development of the Company’s two primary drug candidates consisting of Lucid-MS and Lucid-PSYCH, as well as the development of UNBUZZD. The Company’s Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial real estate property. Lucid-PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. UNBUZZD is a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of potentially quickly relieving from the effects of alcohol consumption, such as inebriation, and restoring normal lifestyle.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-24.83m
  • Incorporated1998
  • Employees10.00
  • Location
    FSD Pharma IncFirst Canadian Place100 King Street West, Suite 4000TORONTO M5X 1A4CanadaCAN
  • Phone+1 (416) 854-8884
  • Fax+1 (416) 854-8884
  • Websitehttps://www.fsdpharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.